BST2 antibody (PE)

Catalog No. ABIN2662602

The PE-conjugated Mouse Monoclonal anti-BST2 antibody (Clone RS38E) (ABIN2662602) specifically detects BST2 in FACS, ICC and ICFC. The antibody is reactive with Human samples.

Quick Overview for BST2 antibody (PE) (ABIN2662602)

Target: BST2 (Bone Marrow Stromal Cell Antigen 2 (BST2))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This BST2 antibody is conjugated to PE

Application: Flow Cytometry (FACS), Immunocytochemistry (ICC), Intracellular Flow Cytometry (ICFC)

Clone: RS38E

Product Details anti-BST2 Antibody (PE)

Cross-Reactivity: Pigtailed Macaque, Rhesus Monkey

Purification: The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for BST2

Target: BST2 (Bone Marrow Stromal Cell Antigen 2 (BST2))

Alternative Name: CD317

Background: CD317, also known as BST2, Tetherin, and HM1.24, is a type II transmembrane GPI-protein with a molecular weight of about 29-33 kD. It is an interferon-induced protein expressed on dendritic cells, plasma cells, B lymphoblast cells, monocytes, granulocytes, T cells, NK cells, stromal cells, and some non-hematopoietic cells. BST2 inhibits cytokine production through interaction with ILT7 (CD85g). It is also involved in the regulation of B cell growth. More importantly, BST2 has been found to restrict the release of a number of viruses from infected cells, including all tested retroviruses (such as HIV-1) and some arenaviruses and filoviruses. In HIV-1 studies, it has been reported that BST2 retains the nascent virons on the surface of infected cells by incorporation of the protein into HIV-1 particles. HIV-1 Vpu is able to induce BST2 degradation.

Pathways: Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response